Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 1 April 2007, Vol. 109, No. 7, pp. 2700-2707.
Prepublished online as a Blood First Edition Paper on November 21, 2006; DOI 10.1182/blood-2006-07-025809.


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
blood-2006-07-025809v1
109/7/2700    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jost, P. J.
Right arrow Articles by Ruland, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jost, P. J.
Right arrow Articles by Ruland, J.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Next Article next article arrow

Submitted July 26, 2006
Accepted November 15, 2006

Aberrant NF-{kappa}B signaling in lymphoma: mechanisms, consequences and therapeutic implications

Philipp J. Jost and Jurgen Ruland*

III. Medizinsche Klinik, Klinikum rechts der Isar, Technische Universitat Munchen, Munich, Germany

* Corresponding author; email: jruland{at}lrz.tum.de.

The transcription factor NF-{kappa}B is a tightly regulated positive mediator of T and B cell development, proliferation and survival. The controlled activity of NF-{kappa}B is required for the coordination of physiological immune responses. However, constitutive NF-{kappa}B activation can promote continuous lymphocyte proliferation and survival and has recently been recognized as a critical pathogenetic factor in lymphoma. Various molecular events lead to deregulation of NF-{kappa}B signaling in Hodgkin's disease and a variety of T and B cell non-Hodgkins lymphomas either upstream or downstream of the central I{kappa}B kinase. These alterations are prerequisites for lymphoma cell cycling and blockage of apoptosis. This review provides an overview of the NF-{kappa}B pathway and discusses the mechanisms of NF-{kappa}B deregulation in distinct lymphoma entities with defined aberrant pathways: Hodgkin's lymphoma (HL), diffuse large B cell lymphoma (DLBCL), MALT-lymphoma, primary effusion lymphoma (PEL) and adult T cell lymphoma/leukemia (ATL). In addition, we summarize recent data that validates the NF-{kappa}B signaling pathway as an attractive therapeutic target in T and B cell malignancies.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
BloodHome page
K. Klapproth, S. Sander, D. Marinkovic, B. Baumann, and T. Wirth
The IKK2/NF-{kappa}B pathway suppresses MYC-induced lymphomagenesis
Blood, September 17, 2009; 114(12): 2448 - 2458.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
R. J. Bende, F. van Maldegem, and C. J.M. van Noesel
Chronic inflammatory disease, lymphoid tissue neogenesis and extranodal marginal zone B-cell lymphomas
Haematologica, August 1, 2009; 94(8): 1109 - 1123.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
T. Hideshima, D. Chauhan, T. Kiziltepe, H. Ikeda, Y. Okawa, K. Podar, N. Raje, A. Protopopov, N. C. Munshi, P. G. Richardson, et al.
Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications
Blood, May 21, 2009; 113(21): 5228 - 5236.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
U. Novak, A. Rinaldi, I. Kwee, S. V. Nandula, P. M. V. Rancoita, M. Compagno, M. Cerri, D. Rossi, V. V. Murty, E. Zucca, et al.
The NF-{kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas
Blood, May 14, 2009; 113(20): 4918 - 4921.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
L. D. Sjo, S. Heegaard, J. U. Prause, B. L. Petersen, S. Pedersen, and E. Ralfkiaer
Extranodal Marginal Zone Lymphoma in the Ocular Region: Clinical, Immunophenotypical, and Cytogenetical Characteristics
Invest. Ophthalmol. Vis. Sci., February 1, 2009; 50(2): 516 - 522.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
J. Murn, O. Alibert, N. Wu, S. Tendil, and X. Gidrol
Prostaglandin E2 regulates B cell proliferation through a candidate tumor suppressor, Ptger4
J. Exp. Med., December 22, 2008; 205(13): 3091 - 3103.
[Abstract] [Full Text] [PDF]


Home page
J. Gen. Virol.Home page
K. Silbermann, G. Schneider, and R. Grassmann
Stimulation of interleukin-13 expression by human T-cell leukemia virus type 1 oncoprotein Tax via a dually active promoter element responsive to NF-{kappa}B and NFAT
J. Gen. Virol., November 1, 2008; 89(11): 2788 - 2798.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
J. R. Cerhan, W. Liu-Mares, Z. S. Fredericksen, A. J. Novak, J. M. Cunningham, N. E. Kay, A. Dogan, M. Liebow, A. H. Wang, T. G. Call, et al.
Genetic Variation in Tumor Necrosis Factor and the Nuclear Factor-{kappa}B Canonical Pathway and Risk of Non-Hodgkin's Lymphoma
Cancer Epidemiol. Biomarkers Prev., November 1, 2008; 17(11): 3161 - 3169.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. H. Coles, C. G.A. Marfella, A. N. Imbalzano, H. A. Steinman, D. S. Garlick, R. M. Gerstein, and S. N. Jones
p37Ing1b Regulates B-Cell Proliferation and Cooperates with p53 to Suppress Diffuse Large B-Cell Lymphomagenesis
Cancer Res., November 1, 2008; 68(21): 8705 - 8714.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
H.-C. Chuang, J.-M. Wang, W.-C. Hsieh, Y. Chang, and I.-J. Su
Up-Regulation of Activating Transcription Factor-5 Suppresses SAP Expression to Activate T Cells in Hemophagocytic Syndrome Associated with Epstein-Barr Virus Infection and Immune Disorders
Am. J. Pathol., November 1, 2008; 173(5): 1397 - 1405.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
G. Yan, J. Huang, N. R. Jarbadan, Y. Jiang, and H. Cheng
Sequestration of NF-{kappa}B Signaling Complexes in Lipid Rafts Contributes to Repression of NF-{kappa}B in T Lymphocytes under Hyperthermia Stress
J. Biol. Chem., May 2, 2008; 283(18): 12489 - 12500.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. Ruland
Signaling crosstalk in DLBCL
Blood, April 1, 2008; 111(7): 3304 - 3304.
[Full Text] [PDF]


Home page
BloodHome page
L. T. Lam, G. Wright, R. E. Davis, G. Lenz, P. Farinha, L. Dang, J. W. Chan, A. Rosenwald, R. D. Gascoyne, and L. M. Staudt
Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma
Blood, April 1, 2008; 111(7): 3701 - 3713.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. V. Bradley, M. R. Smith, T. S. Hyun, P. C. Lucas, L. Li, D. Antonuk, I. Joshi, F. Jin, and T. S. Ross
Aberrant Huntingtin Interacting Protein 1 in Lymphoid Malignancies
Cancer Res., September 15, 2007; 67(18): 8923 - 8931.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020